Strategic News: Liquid Biopsy Market to Hit $7.05B by 2030
The report "Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Application (Lung, Breast, Prostate Cancer), Sample Type (Blood, Urine, CSF), End User (Hospitals) - Global Forecast to 2030", is projected to reach USD 7.05 billion by 2030 from USD 4.03 billion in 2025, at a CAGR of 11.8% during the forecast period.
Browse 482 market data Tables and 60 Figures spread through 392 Pages and in-depth TOC on "Liquid Biopsy Market - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html
Several key factors, including the rising global incidence of cancer and the increasing demand for non-invasive, efficient diagnostic solutions, drive the growth of the liquid biopsy market. Technological advancements in next-generation sequencing (NGS) and digital PCR have significantly improved the sensitivity and specificity of liquid biopsy assays, enhancing their clinical utility. Global cancer awareness campaigns and national screening initiatives are also crucial in promoting early diagnosis, increasing the demand for accessible and patient-friendly testing methods.
By technology, the multi-gene parallel analysis segment accounted for the largest market share in 2024.
The liquid biopsy market is segmented by technology into multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays. In 2024, the multi-gene parallel analysis using NGS segment accounted for the largest share of the market. The large share of this segment is attributed to NGS’s ability to analyze multiple genetic alterations simultaneously, offering comprehensive molecular profiling with high accuracy. Its high-throughput capacity, flexibility, and suitability for detecting complex genomic changes make it ideal for clinical applications such as therapy selection and monitoring. The integration of NGS into personalized medicine strategies and its growing use in routine diagnostics further contribute to market growth.
In 2024, the cancer application segment accounted for the largest market share.
By application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2024, the cancer applications segment accounted for the largest share of the market. This dominance is primarily driven by the rising global incidence of cancer and the increasing volume of research focused on utilizing liquid biopsy in oncology. The segment's growth is further supported by liquid biopsy’s ability to monitor tumor progression in real time, detect minimal residual disease, and overcome limitations associated with traditional tissue biopsies.
In 2024, North America accounted for the largest share of the market.
The liquid biopsy market is segmented into five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest share of the market. The large share of this market is attributed to the region’s well-established healthcare infrastructure, which includes advanced diagnostic capabilities, specialized cancer care centers, and a highly trained medical workforce. These factors collectively support the widespread adoption of liquid biopsy technologies and their integration into routine clinical practice, ensuring broader patient access across diverse healthcare settings.
The leading players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Guardant Health (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), GRAIL, Inc. (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), and Sysmex Corporation (Japan)
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Liquid Biopsy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
